CYRX
What one share of Cryoport holds
Pharmaceutical Preparations
We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy (“CGT”) market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies.
Cryoport’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.72 |
|---|---|
| Profit | −$0.91 |
| Capex (buildings and equipment) | $0.56 |
| Free cash flow | −$0.40 |
| Cash and investments | $5.32 |
| Debt | $3.68 |
| Book value | $9.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | $0.04 | −$0.46 | $0.03 | −$0.39 | — | — |
| 2012 | $0.02 | −$0.27 | $0.01 | −$0.21 | — | $0.10 |
| 2013 | $0.03 | −$0.17 | $0.00 | −$0.13 | — | −$0.05 |
| 2014 | $0.65 | −$4.81 | $0.03 | −$1.11 | — | −$0.46 |
| 2015 | $0.79 | −$2.44 | $0.01 | −$0.84 | — | −$0.08 |
| 2016 | $0.80 | −$2.05 | $0.15 | −$1.01 | — | $0.25 |
| 2016 | $0.54 | −$0.93 | $0.07 | −$0.48 | — | $0.32 |
| 2017 | $0.52 | −$0.34 | $0.07 | −$0.23 | — | $0.70 |
| 2018 | $0.70 | −$0.34 | $0.10 | −$0.22 | — | $1.27 |
| 2019 | $1.02 | −$0.55 | $0.16 | −$0.20 | — | $3.38 |
| 2020 | $2.04 | −$1.94 | $0.23 | −$0.62 | — | $9.61 |
| 2021 | $4.85 | −$6.18 | $0.52 | −$0.34 | — | $12.94 |
| 2022 | $4.84 | −$0.93 | $0.45 | −$0.49 | — | $11.50 |
| 2023 | $3.46 | −$2.21 | $0.80 | −$0.81 | — | $9.99 |
| 2024 | $3.18 | −$2.49 | $0.35 | −$0.68 | — | $8.05 |
| 2025 | $3.52 | $1.40 | $0.33 | −$0.50 | — | $10.08 |